약물에 의한 피부유해반응 = Cutaneous adverse drug reactions

다국어 초록 (Multilingual Abstract)

Background: Cutaneous adverse drug reactions are common and produce easily identifiable clinical symptoms.
These may range from mild maculopapular rashes to severe reactions associated with systemic disease.
Current Concepts: The most common presentation of a drug eruption is in the form of a maculopapular rash or exanthematous skin eruption, followed by fixed drug eruptions and urticaria. Severe cutaneous adverse drug reactions include Stevens-Johnson syndrome/toxic epidermal necrolysis, acute generalized exanthematous pustulosis, and drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms, which are rare but potentially life-threatening. Recently, it has emerged that cutaneous adverse drug reactions associated with newly developed drugs, such as epidermal growth factor receptor inhibitors, may induce a variety of cutaneous manifestations.
Discussion and Conclusion: Although certain drugs, such as antimicrobials and anticonvulsants, can frequently cause drug eruptions, their effects may change, depending on the situation and timing. Therefore, in order to resolve symptoms and prevent complications, early diagnosis, drug identification, and appropriate treatment should be performed, in consideration of the various factors involved.

참고문헌 (Reference)

1 이민영 ; 변지연 ; 최혜영 ; 최유원, "피부과로 협진의뢰된 입원환자의 약진에 대한 임상적 고찰" 대한피부과학회 56 (56): 314-321, 2018

2 류소민 ; 최혜영 ; 변지연 ; 최유원, "피부과로 협진 의뢰된 입원환자의 임상 양상 및 진료과별 특성에 따른 고찰" 대한피부과학회 52 (52): 215-221, 2014

3 Aguiar D, "Toxic epidermal necrolysis in patients receiving anticonvulsants and cranial irradiation : a risk to consider" 66 : 345-350, 2004

4 Barbaud A, "The use of skin testing in the investigation of cutaneous adverse drug reactions" 139 : 49-58, 1998

5 Bentele-Jaberg N, "The phytotherapeutic fenugreek as trigger of toxic epidermal necrolysis" 231 : 99-102, 2015

6 Aydin F, "Stevens-Johnson syndrome in two patients treated with cranial irradiation and phenytoin" 20 : 588-590, 2006

7 Duong TA, "Severe cutaneous adverse reactions to drugs" 390 : 1996-2011, 2017

8 Grover S, "Severe cutaneous adverse reactions" 77 : 3-6, 2011

9 Chung WH, "Severe cutaneous adverse drug reactions" 43 : 758-766, 2016

10 Roujeau JC, "Severe adverse cutaneous reactions to drugs" 331 : 1272-1285, 1994

11 Bastuji-Garin S, "SCORTEN : a severity-of-illness score for toxic epidermal necrolysis" 115 : 149-153, 2000

12 Rzany B, "Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis during first weeks of antiepileptic therapy : a case-control study : study group of the international case control study on severe cutaneous adverse reactions" 353 : 2190-2194, 1999

13 Sidoroff A, "Risk factors for acute generalized exanthematous pustulosis(AGEP)-results of a multinational case-control study(EuroSCAR)" 157 : 989-996, 2007

14 Bigby M, "Rates of cutaneous reactions to drugs" 137 : 765-770, 2001

15 Josephs SH, "Phenytoin hypersensitivity" 66 : 166-172, 1980

16 Goutham S, "Patterns of cutaneous drug reactions : a review" 2 : 134-137, 2019

17 Yip LW, "Ocular manifestations and complications of Stevens-Johnson syndrome and toxic epidermal necrolysis : an Asian series" 62 : 527-531, 2007

18 Mizukawa Y, "In vivo dynamics of intraepidermal CD8+ T cells and CD4+ T cells during the evolution of fixed drug eruption" 158 : 1230-1238, 2008

19 Yang CH, "Hand-foot skin reaction in patients treated with sorafenib : a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy" 158 : 592-596, 2008

20 Barbaud A, "Guidelines for performing skin tests with drugs in the investigation of cutaneous adverse drug reactions" 45 : 321-328, 2001

21 Shiohara T, "Fixed drug eruption : pathogenesis and diagnostic tests" 9 : 316-321, 2009

22 Heelan K, "Fitzpatrick’s dermatology" McGraw-Hill 749-764, 2019

23 Tan EK, "Drug-induced urticaria" 3 : 471-484, 2004

24 Valeyrie-Allanore L, "Drug-induced skin, nail and hair disorders" 30 : 1011-1030, 2007

25 Bocquet H, "Drug-induced pseudolymphoma and drug hypersensitivity syndrome(Drug Rash with Eosinophilia and Systemic Symptoms : DRESS)" 15 : 250-257, 1996

26 Bigby M, "Drug-induced cutaneous reactions : a report from the Boston Collaborative Drug Surveillance Program on 15, 438 consecutive inpatients, 1975to 1982" 256 : 3358-3363, 1986

27 Nigen S, "Drug eruptions : approaching the diagnosis of drug-induced skin diseases" 2 : 278-299, 2003

28 Choi YW, "Drug eruption" 35 : 76-82, 2012

29 Magina S, "Dermatological and ophthalmological sequels in toxic epidermal necrolysis" 207 : 33-36, 2003

30 Habre M, "Dermatologic adverse events of checkpoint inhibitors : what an oncologist should know" 8 : 1437-1446, 2016

31 Robert C, "Cutaneous side-effects of kinase inhibitors and blocking antibodies" 6 : 491-500, 2005

32 Patel TK, "Cutaneous adverse drug reactions in Indian population : a systematic review" 5 (5): S76-, 2014

33 La Grenade L, "Comparison of reporting of Stevens-Johnson syndrome and toxic epidermal necrolysis in association with selective COX-2 inhibitors" 28 : 917-924, 2005

34 Shin KS, "Clinical study of hospitalized patients with drug eruption during a 10-year period(1976–1985)" 25 : 176-182, 1987

35 Chang KY, "Clinical study and skin tests of patients with drug eruptions" 36 : 997-1004, 1998

36 Kim KJ, "Clinical study and skin tests of patients with drug eruptions" 36 : 887-896, 1998

37 Kim KY, "Clinical study and skin tests of patients with drug eruptions" 31 : 681-690, 1993

38 Segaert S, "Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors" 16 : 1425-1433, 2005

39 Miller KK, "Chemotherapy-induced hand-foot syndrome and nail changes : a review of clinical presentation, etiology, pathogenesis, and management" 71 : 787-794, 2014

40 Young-Min Son ; 이종록 ; 노주영, "Causality Assessment of Cutaneous Adverse Drug Reactions" 대한피부과학회 23 (23): 432-438, 2011

41 Pérez-Soler R, "Can rash associated with HER1/EGFR inhibition be used as a marker of treatment outcome?" 17 (17): 23-28, 2003

42 Häusermann P, "Baboon syndrome resulting from systemic drugs : is there strife between SDRIFE and allergic contact dermatitis syndrome?" 51 : 297-310, 2004

43 Hua C, "Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab" 152 : 45-51, 2016

44 Anderson JA, "Allergic reactions to drugs and biologic agents" 258 : 2891-2899, 1987

45 Chatterjee S, "Adverse cutaneous drug reactions : a one year survey at a dermatology outpatient clinic of a tertiary care hospital" 38 : 429-431, 2006

46 Nayak S, "Adverse cutaneous drug reaction" 53 : 2-8, 2008

47 Hoetzenecker W, "Adverse cutaneous drug eruptions : current understanding" 38 : 75-86, 2016

48 Ofuji S, "Acute generalized exanthematous pustulosis associated with a human parvovirus B19 infection" 34 : 121-123, 2007

49 Jha N, "A study of cutaneous adverse drug reactions in a tertiary care center in Punjab" 9 : 299-303, 2018

50 Bang DS, "A statistical study of dermatoses during the last 5 years(1976–1980)" 21 : 37-44, 1983